AAAAAA

   
Results: 1-8 |
Results: 8
SLOWING THE PROGRESSION OF ALZHEIMER-DISEASE - MONITORING PROGRESSION- DISCUSSION
Authors: MCGEER P ROSSOR MN BODICK NC
Citation: P. Mcgeer et al., SLOWING THE PROGRESSION OF ALZHEIMER-DISEASE - MONITORING PROGRESSION- DISCUSSION, Alzheimer disease and associated disorders, 11, 1997, pp. 9-9
PHARMACOECONOMICS OF DEMENTIA - DISCUSSION
Authors: BODICK NC WHITEHOUSE PJ LEVKOFF S
Citation: Nc. Bodick et al., PHARMACOECONOMICS OF DEMENTIA - DISCUSSION, Alzheimer disease and associated disorders, 11, 1997, pp. 32-33
THE SELECTIVE MUSCARINIC AGONIST XANOMELINE IMPROVES BOTH THE COGNITIVE DEFICITS AND BEHAVIORAL SYMPTOMS OF ALZHEIMER-DISEASE
Authors: BODICK NC OFFEN WW SHANNON HE SATTERWHITE J LUCAS R VANLIER R PAUL SM
Citation: Nc. Bodick et al., THE SELECTIVE MUSCARINIC AGONIST XANOMELINE IMPROVES BOTH THE COGNITIVE DEFICITS AND BEHAVIORAL SYMPTOMS OF ALZHEIMER-DISEASE, Alzheimer disease and associated disorders, 11, 1997, pp. 16-22
XANOMELINE - A SELECTIVE MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE
Authors: BYMASTER FP WHITESITT CA SHANNON HE DELAPP N WARD JS CALLIGARO DO SHIPLEY LA BUELKESAM JL BODICK NC FARDE L SHEARDOWN MJ OLESEN PH HANSEN KT SUZDAK PD SWEDBERG MDB SAUERBERG P MITCH CH
Citation: Fp. Bymaster et al., XANOMELINE - A SELECTIVE MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE, Drug development research, 40(2), 1997, pp. 158-170
EFFECTS OF XANOMELINE, A SELECTIVE MUSCARINIC RECEPTOR AGONIST, ON COGNITIVE FUNCTION AND BEHAVIORAL SYMPTOMS IN ALZHEIMER-DISEASE
Authors: BODICK NC OFFEN WW LEVEY AI CUTLER NR GAUTHIER SG SATLIN A SHANNON HE TOLLEFSON GD RASMUSSEN K BYMASTER FP HURLEY DJ POTTER WZ PAUL SM
Citation: Nc. Bodick et al., EFFECTS OF XANOMELINE, A SELECTIVE MUSCARINIC RECEPTOR AGONIST, ON COGNITIVE FUNCTION AND BEHAVIORAL SYMPTOMS IN ALZHEIMER-DISEASE, Archives of neurology, 54(4), 1997, pp. 465-473
COGNITIVE IMPROVEMENT IN ALZHEIMERS-DISEASE - USE OF THE CNTB IN A TRIAL OF XANOMELINE
Authors: CUTLER NR VEROFF AE BODICK NC OFFEN WW SRAMEK JJ
Citation: Nr. Cutler et al., COGNITIVE IMPROVEMENT IN ALZHEIMERS-DISEASE - USE OF THE CNTB IN A TRIAL OF XANOMELINE, Biological psychiatry, 39(7), 1996, pp. 545-545
SINGLE AND MULTIPLE-DOSE SAFETY, PHARMACODYNAMICS AND PHARMACOKINETICS OF XANOMELINE, A NOVEL MUSCARINIC M1 AGONIST IN HEALTHY MALE-SUBJECTS
Authors: BODICK NC SATTERWHITE JH LUCAS RA HEATON J CARTER GV
Citation: Nc. Bodick et al., SINGLE AND MULTIPLE-DOSE SAFETY, PHARMACODYNAMICS AND PHARMACOKINETICS OF XANOMELINE, A NOVEL MUSCARINIC M1 AGONIST IN HEALTHY MALE-SUBJECTS, Neurobiology of aging, 15, 1994, pp. 190000104-190000105
XANOMELINE, A POTENT AND SPECIFIC M1 AGONIST IN THE TREATMENT OF MILDAND MODERATE ALZHEIMERS-DISEASE
Authors: BODICK NC SHANNON HC SYMANOWSKI S
Citation: Nc. Bodick et al., XANOMELINE, A POTENT AND SPECIFIC M1 AGONIST IN THE TREATMENT OF MILDAND MODERATE ALZHEIMERS-DISEASE, Neurobiology of aging, 15, 1994, pp. 190000148-190000148
Risultati: 1-8 |